Detalles de la búsqueda
1.
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies.
J Immunol
; 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38767437
2.
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Lancet Oncol
; 25(5): 588-602, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38608691
3.
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Cancer Immunol Immunother
; 73(7): 116, 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38713408
4.
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
Cancer
; 126(3): 523-530, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31658370
5.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol
; 20(10): 1370-1385, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31427204
6.
Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study.
Hered Cancer Clin Pract
; 17: 27, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31528241
7.
Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis.
South Med J
; 112(3): 154-158, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30830228
8.
Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
Breast Cancer Res Treat
; 161(2): 191-201, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27826754
9.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Lancet Oncol
; 17(7): 883-895, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27269741
10.
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Cancer Immunol Immunother
; 65(12): 1533-1544, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27714434
11.
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
BMC Cancer
; 16(1): 673, 2016 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-27553291
12.
Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome.
Cancer Immunol Immunother
; 63(12): 1329-40, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25205170
13.
Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Breast Cancer Res Treat
; 145(3): 775-84, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24800917
14.
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).
J Immunother Cancer
; 12(2)2024 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38316517
15.
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
Cancer Immun
; 13: 7, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23833564
16.
Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.
BMC Cancer
; 13: 312, 2013 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-23806170
17.
High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?
Oncology (Williston Park)
; 27(7): 680-91, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23977763
18.
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.
Cancer Res Commun
; 2(8): 894-903, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36923304
19.
Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model.
Cancer Immunol Immunother
; 60(9): 1347-56, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21638127
20.
Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
Thromb Res
; 208: 71-78, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34742139